Lipocine (LPCN) Announces Positive Topline Data from LPCN 1111 Phase 2b as TRT
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy
September 26, 2016 8:01 AM EDTOnce-daily dose identified for the pivotal Phase 3 studyWell tolerated with no drug-related severe or serious adverse events reported
SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today reported positive top-line results from a Phase 2b clinical study of LPCN 1111, a novel oral testosterone replacement therapy ("TRT") product candidate. The primary... More
